• ABPI Website
  • Media
  • ABPI Board announces Kate Brunner QC appointed as new Chair of the PMCPA Appeal Board

ABPI Board announces Kate Brunner QC appointed as new Chair of the PMCPA Appeal Board

The ABPI Board is pleased to announce that Kate Brunner QC has been appointed Chair of the PMCPA Appeal Board. This follows the announcement that the current Chair, Mr William Harbage QC, is stepping down from the role at the end of 2020, after 15 years in the role.

The PMCPA plays a critical role in upholding the high standards under which the industry operates, and I’m committed to using my experience to champion successful self-regulation in the pharmaceutical industry. Kate Brunner QC
The ABPI Board welcomes Kate Brunner QC into the role of Chair of the PMCPA Appeal Board. Haseeb Ahmad

ABPI President and Chair of the ABPI Board, Haseeb Ahmad, said:

“The ABPI Board welcomes Kate Brunner QC into the role of Chair of the PMCPA Appeal Board. Ms Brunner brings a huge breadth of experience to the role, across a wide-ranging legal practice including criminal, regulatory, and healthcare law. I look forward to working with Kate and the PMCPA to ensure there is a smooth transition in the new year.”

Kate Brunner QC said:

“I am delighted to take on such an important role as the independent Chair of the PMCPA Appeal Board. 

“The PMCPA plays a critical role in upholding the high standards under which the industry operates, and I’m committed to using my experience to champion successful self-regulation in the pharmaceutical industry.”

TAGS
  • PMCPA

Last modified: 20 September 2023

Last reviewed: 20 September 2023

The ABPI exists to make the UK the best place in the world to research, develop and use new medicines. We represent companies of all sizes who invest in discovering the medicines of the future. 

Our members supply cutting edge treatments that improve and save the lives of millions of people. We work in partnership with Government and the NHS so patients can get new treatments faster and the NHS can plan how much it spends on medicines. Every day, we partner with organisations in the life sciences community and beyond to transform lives across the UK.